Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring in Wednesday’s after-hours session after the company announced a ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Sarepta (SRPT) plans to continue Elevidys shipments for Duchenne muscular dystrophy, despite FDA request not to do so after ...

Sarepta Therapeutics (NASDAQ:SRPT) saw its stock rise in after-hours trading following the announcement of a strategic review ...

High-rolling investors have positioned themselves bullish on Sarepta Therapeutics (NASDAQ:SRPT), and it's important for retail traders to take note. \This activity came to our attention today ...

Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $106.75, a high estimate of $202.00, and a low estimate of $75.00.

Sarepta Therapeutics (NASDAQ:SRPT) has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The table below provides a concise ...

Ratings for Sarepta Therapeutics (NASDAQ:SRPT) were provided by 25 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.The table below provides a snapshot of ...

It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT). Shares have added about 4.9% in that time frame, outperforming the S&P 500.

Investors in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) had a good week, as its shares rose 3.3% to close at US$87.11 following the release of its yearly results. The statutory results were mixed ...

Deep-pocketed investors have adopted a bullish approach towards Sarepta Therapeutics (NASDAQ:SRPT), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $164.08, a high estimate of $185.00, and a low estimate of $128.00.